Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, Controlled, Double-Blind Study

被引:58
|
作者
Spaniel, Filip [1 ]
Hrdlicka, Jan [2 ]
Novak, Tomas [1 ]
Kozeny, Jiri [1 ]
Hoeschl, Cyril [1 ]
Mohr, Pavel [1 ]
Motlova, Lucie Bankovska [1 ]
机构
[1] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Ctr Neuropsychiat Studies, Prague 18103 8, Czech Republic
[2] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic
关键词
schizophrenia; psychotic disorders; relapse prevention; hospitalizations; antipsychotic medication; information technology; FOLLOW-UP; THERAPY; PREDICTION; SYMPTOMS; EPISODE; COSTS; SIGNS;
D O I
10.1097/01.pra.0000416017.45591.c1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose. To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). Methods. Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n = 75) or control group (n = 71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological intervention requiring event (PIRE) detected by ITAREPS. Results. Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR] = 10.8; 95% confidence interval [CI] 1.4-80.0; p = 0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n = 25) compared with the ITAREPS Non-interventional group (INIs, n = 70; Kaplan-Meier survival analysis, HR = 0.11, 95% CI 0.05-0.28, p = 0.009; number needed to treat [NNT] = 4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p < 0.05) and costs (p < 0.05). Conclusion. Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. Trial registration: Clinical Trials NCT00712660 (Journal of Psychiatric Practice 2012; 18: 269-280)
引用
收藏
页码:269 / 280
页数:12
相关论文
共 50 条
  • [11] Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study
    Michelson, D
    Buitelaar, JK
    Danckaerts, M
    Gillberg, C
    Spencer, TJ
    Zuddas, A
    Faries, DE
    Zhang, SY
    Biederman, J
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2004, 43 (07): : 896 - 904
  • [12] Relapse prevention in schizophrenia: Evidence from long-term, randomized, double-blind clinical trials
    Pecenak, Jan
    NEUROENDOCRINOLOGY LETTERS, 2007, 28 : 49 - 70
  • [13] COST-EFFECTIVENES ANALYSIS OF THE INFORMATION TECHNOLOGY AIDED RELAPS PREVENTION PROGRAME IN SCHIZOPHRENIA (ITAREPS) IN THE CZECH REPUBLIC
    Mlcoch, T.
    Kruntoradova, K.
    Mandelikova, M.
    Dolezal, T.
    VALUE IN HEALTH, 2015, 18 (07) : A410 - A410
  • [14] Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study
    Forray, Ariadna
    Gilstad-Hayden, Kathryn
    Suppies, Cristine
    Bogen, Debra
    Sofuoglu, Mehmet
    Yonkers, Kimberly A.
    PSYCHONEUROENDOCRINOLOGY, 2017, 86 : 96 - 103
  • [15] Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study
    Loebel, Antony
    Cucchiaro, Josephine
    Xu, Jane
    Sarma, Kaushik
    Pikalov, Andrei
    Kane, John M.
    SCHIZOPHRENIA RESEARCH, 2013, 147 (01) : 95 - 102
  • [16] Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer - A multicentre, double-blind, parallel, randomized, controlled study
    Tulassay, Z
    Dobronte, Z
    Farkas, I
    Juhasz, L
    Simon, L
    Pronai, L
    Torres, J
    Marquez, M
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47-1 (4A): : 551 - 555
  • [17] Sustained remission with cariprazine treatment: post hoc analysis of a randomized, double-blind, schizophrenia relapse prevention trial
    Correll, C. U.
    Potkin, S. G.
    Durgam, S.
    Cheng, C. T.
    Szatmari, B.
    Laszlovszky, I.
    Saliu, I.
    Earley, W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S935 - S936
  • [18] LOXAPINE SUCCINATE - CONTROLLED DOUBLE-BLIND STUDY IN SCHIZOPHRENIA
    CHARALAMPOUS, KD
    FREEMESSER, GF
    MALEV, J
    FORD, K
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1974, 16 (08): : 829 - 837
  • [19] Adjunctive Memantine Treatment of Schizophrenia A Double-Blind, Randomized Placebo-Controlled Study
    Hassanpour, Fatemeh
    Zarghami, Mehran
    Mouodi, Sussan
    Moosazadeh, Mahmood
    Barzegar, Fatemeh
    Bagheri, Maedeh
    Hendouei, Narjes
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (06) : 634 - 638
  • [20] Duloxetine in the prevention of relapse of major depressive disorder - Double-blind placebo-controlled study
    Perahia, DG
    Gilaberte, I
    Wang, FJ
    Wiltse, CG
    Huckins, SA
    Clemens, JW
    Montgomery, SA
    Montejo, AL
    Detke, MJ
    BRITISH JOURNAL OF PSYCHIATRY, 2006, 188 : 346 - 353